CA2222103A1 - Inositolglycans having insulin-like action - Google Patents

Inositolglycans having insulin-like action

Info

Publication number
CA2222103A1
CA2222103A1 CA002222103A CA2222103A CA2222103A1 CA 2222103 A1 CA2222103 A1 CA 2222103A1 CA 002222103 A CA002222103 A CA 002222103A CA 2222103 A CA2222103 A CA 2222103A CA 2222103 A1 CA2222103 A1 CA 2222103A1
Authority
CA
Canada
Prior art keywords
alkyl
inositolglycans
insulin
action
r1r2n
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002222103A
Other languages
French (fr)
Other versions
CA2222103C (en
Inventor
Wendelin Frick
Gunter Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst Aktiengesellschaft
Wendelin Frick
Gunter Muller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Aktiengesellschaft, Wendelin Frick, Gunter Muller filed Critical Hoechst Aktiengesellschaft
Publication of CA2222103A1 publication Critical patent/CA2222103A1/en
Application granted granted Critical
Publication of CA2222103C publication Critical patent/CA2222103C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04Disaccharides

Abstract

Inositolglycans having insulin-like action Compounds of the formula I

A-Z-R (I) are described, where A is the radical H - P(O)(OH) -, H - P(S)(OH) -, HO--P(S)(OH) -, HS-P(S)(OH) -, (C1-C4) - alkyl - P(O)(OH) -, (C1-C4) - alkyl -P(S)(OH)-, S(O)2(OR1) -, S(O)(OR1)-, NH2 - C(O) -, R1R2N -, R1R2N - C(O) -NH -, R1O - SO2 - NH -, (C1-C4) - alkyl - SO2 -, (C1-C4) - alkyl - S(O) - or R1 - S -, Z is 2 to 6 substituted or unsubstituted sugar radicals and R is substituted or unsubstituted inositol.
The compounds of the formula I are suitable for the treatment of diabetes mellitus or noninsulin-dependent diabetes.
CA002222103A 1996-11-28 1997-11-25 Inositolglycans having insulin-like action Expired - Fee Related CA2222103C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19649350.1 1996-11-28
DE19649350A DE19649350A1 (en) 1996-11-28 1996-11-28 Inositol glycans with an insulin-like effect

Publications (2)

Publication Number Publication Date
CA2222103A1 true CA2222103A1 (en) 1998-05-28
CA2222103C CA2222103C (en) 2007-08-28

Family

ID=7813041

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222103A Expired - Fee Related CA2222103C (en) 1996-11-28 1997-11-25 Inositolglycans having insulin-like action

Country Status (19)

Country Link
US (1) US6004938A (en)
EP (1) EP0845475B1 (en)
JP (1) JP4299378B2 (en)
CN (1) CN1136224C (en)
AR (1) AR018246A1 (en)
AT (1) ATE290541T1 (en)
AU (1) AU728637B2 (en)
BR (1) BR9706041C1 (en)
CA (1) CA2222103C (en)
CZ (1) CZ294886B6 (en)
DE (2) DE19649350A1 (en)
DK (1) DK0845475T3 (en)
ES (1) ES2237784T3 (en)
HK (1) HK1008786A1 (en)
HU (1) HUP9702242A3 (en)
PL (1) PL188604B1 (en)
PT (1) PT845475E (en)
RU (1) RU2178794C2 (en)
TR (1) TR199701432A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
GB9814039D0 (en) * 1998-06-29 1998-08-26 Univ London Materials and methods relating to the prevention or treatment of ischaemia-reperfusion injury
US6953781B2 (en) 2000-05-12 2005-10-11 Rodaris Pharmaceuticals Limited Compounds and their uses
US6759390B2 (en) 2000-05-12 2004-07-06 Manuel Martin-Lomas Compounds and their uses
US6716826B2 (en) 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
EP1409498B1 (en) * 2000-05-12 2008-03-26 Rodaris Pharmaceuticals Limited Inositol phosphoglycan derivatives and their medical uses
US6939857B2 (en) 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
CA2433183A1 (en) * 2000-05-12 2001-11-15 Rodaris Pharmaceuticals Limited Inositolglycans and their uses
DE60133137D1 (en) * 2000-05-12 2008-04-17 Rodaris Pharmaceuticals Ltd INOSITOLPHOSPHOGLYCANDERIVATE AND ITS MEDICAL USE
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
FR2828206B1 (en) * 2001-08-03 2004-09-24 Centre Nat Rech Scient USE OF LYSYL OXIDASE INHIBITORS FOR CELL CULTURE AND TISSUE ENGINEERING
EP1503768B1 (en) * 2002-04-29 2015-10-28 NormOxys, Inc. Inositol pyrophosphates, and use thereof
US7943594B2 (en) * 2002-07-10 2011-05-17 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
CN100369610C (en) * 2002-10-09 2008-02-20 中国药科大学 Plant extract for preventing and treating diabetes, and preparing method and pharmaceutic use thereof
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
FR2878850B1 (en) * 2004-12-02 2008-10-31 Cis Bio Internat Sa DERIVATIVES OF INOSITOL-1-PHOSPHATE
EP2114414B1 (en) * 2006-12-21 2013-11-06 Trustees Of Tufts College Synthetic lipophilic inositol glycans for treatment of cancer and glucose-metabolism disorders
EP2111226A4 (en) * 2006-12-29 2010-02-10 Normoxys Inc Cyclitols and their derivatives and their therapeutic applications
EP2152085A4 (en) * 2007-05-01 2012-05-23 Normoxys Inc Erythropoietin complementation or replacement

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446064A (en) * 1980-12-19 1984-05-01 The University Of Virginia Alumni Patents Foundation Insulin mediator substance
DE3326472A1 (en) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt NEW INSULIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AND PHARMACEUTICAL AGENTS FOR TREATING THE DIABETES MELLITUS
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
US4906468A (en) * 1986-04-11 1990-03-06 The Rockefeller University Insulin activity messengers, their antibodies, and thereof
YU66892A (en) * 1991-08-20 1995-10-24 Hoechst Ag. PHOSPHOINOSYTOLGLICAN - A PEPTID WITH ACTION AS INSULIN
EP0545198B1 (en) * 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptides with insulin like activity
JPH06293790A (en) * 1993-04-08 1994-10-21 Kyowa Hakko Kogyo Co Ltd Physiologically active substance, inositol glucan
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances

Also Published As

Publication number Publication date
AU728637B2 (en) 2001-01-11
HK1008786A1 (en) 1999-05-21
JP4299378B2 (en) 2009-07-22
MX9709207A (en) 1998-05-31
RU2178794C2 (en) 2002-01-27
AR018246A1 (en) 2001-11-14
DE19649350A1 (en) 1998-06-04
CZ377597A3 (en) 1998-06-17
HUP9702242A3 (en) 1999-01-28
PL188604B1 (en) 2005-03-31
CZ294886B6 (en) 2005-04-13
ES2237784T3 (en) 2005-08-01
PT845475E (en) 2005-06-30
BR9706041C1 (en) 2000-06-06
EP0845475A1 (en) 1998-06-03
TR199701432A2 (en) 1998-06-22
HU9702242D0 (en) 1998-03-02
DE59712220D1 (en) 2005-04-14
DK0845475T3 (en) 2005-06-27
CN1184112A (en) 1998-06-10
US6004938A (en) 1999-12-21
HUP9702242A1 (en) 1998-12-28
BR9706041A (en) 1999-11-23
PL323407A1 (en) 1998-06-08
EP0845475B1 (en) 2005-03-09
JPH10158291A (en) 1998-06-16
ATE290541T1 (en) 2005-03-15
CA2222103C (en) 2007-08-28
AU4538297A (en) 1998-06-04
CN1136224C (en) 2004-01-28

Similar Documents

Publication Publication Date Title
CA2222103A1 (en) Inositolglycans having insulin-like action
AU8163394A (en) Treatment of diabetes by administration of myo-inositol
CA2103462A1 (en) X-Ray Contrast Agent
CA2048110A1 (en) Imidazopyridine derivatives and their use
CA2060928A1 (en) Dental/medical composition and use
CA2215233A1 (en) Terminal carboxy or tetrazole groups containing dialkyl ethers
CA2056971A1 (en) Improved platy pigments
CA2211314A1 (en) A process for preparing certain aza cyclohexapeptides
CA2205275A1 (en) Vitamin d3 analogs
AU6745696A (en) The preparation of fluorinated organic compounds
CA2166467A1 (en) Sunscreen agents
AU584426B2 (en) Compounds having a polymerizable acylurethane structure, and their production and use
CA2204478A1 (en) Fluorinated vitamin d3 analogs
AU5000193A (en) Antithrombotic treatment with calix(n)arene compounds
IE800477L (en) Pyrimidine derivatives
CA2237897A1 (en) 25-hydroxy-16-ene-26,27-bishomo-cholecalciferols
AU6752990A (en) Combatting slime-forming microorganisms
CA2042535A1 (en) Process for the preparation of intermediates useful for the synthesis of benzothiazepines
CA2092694A1 (en) Use of pyridylmethylsulphinyl-1h-benzimidazole derivates in the treatment of illnesses caused by helicobacter bacteria
WO1997020937A3 (en) Modification process
AU1032392A (en) Multi-pressure compensation of variable displacement pump
CA2083361A1 (en) Fish production
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
CA2123083A1 (en) Uses of 1,1,1,3,3,3-hexafluoropropane
CA2034979A1 (en) Antibiotic, deoxymulundocandin, a process for its production and its useas medicament

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed